| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcb0dde0aefda78540321dfccbddb40a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2019-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e68eb599338c2e5621773058e9a97582 |
| publicationDate |
2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112888441-A |
| titleOfInvention |
Treatment of B-cell malignancies |
| abstract |
Provided herein are methods of treating cancer using phosphoinositide-3-kinase (PI3K) inhibitors. In certain embodiments, the cancer is follicular lymphoma (FL). In certain embodiments, the PI3K inhibitor is administered on a continuous dosing schedule (CS). In other embodiments, the PI3K inhibitor is administered on an intermittent dosing schedule (IS). |
| priorityDate |
2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |